For any OU-affiliated startups (e.g. alumni, faculty, staff, students, etc) that might be interested in the OU Startup Incubator at the Tom Love Innovation Hub. The no-cost Incubator provides dedicated office and workspace as well as personalized mentorship and expertise to launch these promising startups. Tenants get full access to the Tom Love Innovation Hub and have the opportunity to work alongside Start-Hub Fellows – a group of more than 50 students with skills sets in technology, design and business. For startups in OKC, Tulsa, or other areas outside of Norman, they can still apply to the Incubator and take advantage of virtual participating in the incubator until they are able to establish comparable programs on the OUHSC and OU-Tulsa campuses. Applications are due September 3, 2021 - so they are asking everyone interested to apply as soon as possible: https://lnkd.in/dKX8Hram
Save the Date – ORA Noon Conference offered via Zoom
September 29, 2021 at 1:00 pm
Topic: Writing Manuscripts
Description: Communicating the results of your research is an important part of the research enterprise. This presentation will cover how to write original articles and provide tools necessary to successfully write, submit, and publish a manuscript. It will introduce the purpose of each section of a research article, describe the recommended approach, and provide information about common mistakes in writing for biomedical publications. APA’s Journal Article Reporting Standards (JARS) will also be introduced. Please register in advance for this meeting: https://zoom.us/meeting/register/tJcvd-mopz4oHddDFLFtcGLzuQaM3nQpo8Sq After registering, you will receive a confirmation email containing information about joining the meeting.
PLEASE NOTE: Change to OUHSC new NIH Other Support pages requirements. OUHSC will not start implementing this policy internally until October 01, 2021 (previously July 1, 2021). Please keep in mind, that other institutions may have already implemented this policy and you may be required to use the new format for them before the OUHSC October 01, 2021 date.
OSCTR TPIR Trainee Program
Seeking applicants for the eighth year of the research training program Translating Practice into Research (TPIR). TPIR is a program for healthcare professionals, clinical investigators, basic scientists, and community health professionals and it is funded by the NIH Oklahoma Shared Clinical and Translational Resources grant. The goal of the TPIR trainee program is to produce a group of clinicians and scientists who have the ability to translate their clinical observations and ideas for improving practice into practical and feasible research projects. Attached is a detailed description and application due September 20, 2021. http://octsi.ouhsc.edu/Translating Practice into Research
Harold Hamm Diabetes Center (HHDC) - Please mark your calendar for the 18th Annual Harold Hamm Diabetes Center Research Symposium. This in-person event will be held on Friday, November 12, 2021 at the Samis Education Center at Children’s Hospital in Oklahoma City. Deadline for abstracts will be announced in the coming weeks. Additional details will be posted on http://haroldhamm.org/ Questions? Please email Katie-Hoefling@ouhsc.edu
OUHSC American Cancer Society - Institutional Research Grant Program - FALL 2021
Purpose: ACS-IRG grants are designed to support the development of beginning investigators who have no national peer-reviewed research grant support. The program supports junior faculty conducting cancer research pilot projects to obtain preliminary results that will enable them to compete successfully for national research grants.
Eligibility: Full time Assistant Professors within six years of their first independent faculty appointment and with no active peer-reviewed research funding from national funding agencies (e.g. NIH, DOD, NSF, ACS) may apply.
Funding: Up to $50,000 per award for one year. The SCC will fund up to four awards for the FALL 2021 cycle.
Deadline for application: September 10, 2021, 5 PM.
Please refer to the flyer (attached) for application link and guidelines.
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email email@example.com or firstname.lastname@example.org).
- Johnson & Johnson Innovation is seeking collaborations with academics in the area of cell line engineering, with a particular interest in inducible expression of exogenous transgenes integrated into the genome of human HEK293 cells to allow controlled expression from suspension cultures in a large bioreactor. Approaches of interest include: transcription factors, ligand-activated nuclear hormone receptors, riboswitches, and ligands that modulate RNA splicing. Out of scope: post-translational modification approaches, temperature or light-activated approaches.
Submission entails a 1-pg non-confidential summary of technology and supporting validation data (deadline 9/10).
- A global electronics manufacturing company (requested anonymity) is looking to fund projects for the development of consumer electronic devices. Technologies of interest include: imaging sensors, AI for creating mapping information, non-invasive blood glucose sensing, non-contact human signal monitoring sensors, wearable products, innovative robotics, etc. Out of scope: non-validated technology. Submission entails a 1-pg non-confidential summary of technology (deadline 9/17).
- one.five is a biotech platform startup company aiming to scale applied material science, specifically polymer coating technologies pertaining to paper or pulp-based substrates. Out of scope: coating technologies that do not optimize coat weight or use of materials, technologies using rigid materials. Research should be scalable to market within 1-5 years. Submission entails a 1-pg non-confidential summary of technology (deadline 9/24).
Effective immediately, all Human Subject Research (HSR) activities including clinical trials are allowed to resume provided all OUHSC COVID-19 safety protocols can be met. It is expected that all personnel will adhere to the requirements in the OUHSC COVID-19 Response Plan. If your current HSR protocol was temporarily halted due to the COVID-19 restrictions, the HRPP Office will update the study status of those protocols without any actionrequired from you. Also, in accordance with campus policy, our research laboratories* remain closed to K-12 students for shadowing, volunteer, and educational purposes, but open to visitors, undergraduates, graduates, and post-docs from any institution for those purposes, provided the following are observed by these individuals. The manager of the area where these individuals will be is responsible for compliance:
- individuals will be required to show proof of a negative COVID test (within past 48 hours) or documentation of COVID vaccination, if required based on screening results
- all individuals will complete the HSC online COVID-19 training module in OnPoint, using their HSC credentials
- all individuals (including students, faculty, staff, and volunteers) will comply with OU’s COVID-19 vaccine policy:
- those with patient-facing or research participant-facing responsibilities or who will be in patient care or human research participant settings must be vaccinated against COVID-19
- all other individuals will be strongly encouraged to be vaccinated against COVID-19
* all individuals will be informed that they must comply with and be given the link to the HSC COVID-19 Response Plan
*Rotations in clinical areas on campus and at OUMI are limited to OUHSC students, at least through July 2021. With these changes, we are retiring the Return to Research Plan and will refer to the OUHSC COVID Response Plan for COVID protocols. If you identify a deficiency caused by this action, please email email@example.com.
Notice of Pre-Application Webinar for Acquired Resistance to Therapy Network (ARTNet) and its Coordinating and Data Management Center (RFA-CA-21-052 and RFA-CA-21-053) (NOT-CA-21-111)
Continuation of Temporary Extension of Applicant Eligibility in "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00)" Funding Opportunity Announcements (NOT-GM-21-057)
Notice of Informational Webinar on the NIH Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Program Funding Opportunity Announcements (K99/R00 and UE5) (NOT-GM-21-061)
Notice of NHLBI Participation on NOT-ES-21-009: Request for Information (RFI): Climate Change and Health (NOT-HL-21-028)
Notice Announcing the Human BioMolecular Atlas Program (HuBMAP) Integration, Visualization & Engagement (HIVE) Collaboratory (OT2) Other Transaction Opportunity Announcement (NOT-RM-21-031)
Request for Information (RFI): Systematic Review Centers with Nutrition Expertise for DRI Development (NOT-OD-21-173)
Notice of Correction to RFA-CA-21-048, "Research Centers for Cancer Systems Biology (U54 Clinical Trial Not Allowed)" (NOT-CA-21-109)
Notice of Change in Key Dates and Application Types for RFA-DA-23-001, "Exploiting in Vivo or in Situ Imaging Approaches to Understand HIV-relevant Processes In The Context of Substance Use Disorders (R61/R33 Clinical Trials Optional)" (NOT-DA-21-073)
Notice of Correction to the Open Date (Earliest Submission Date) of RFA-HG-21-001, Technology Development for Single-Molecule Protein Sequencing and Single-Cell Proteome Analysis (R01 Clinical Trial not allowed) (NOT-HG-21-042)
Notice of Correction to the Open Date (Earliest Submission Date) of PAR-21-247, Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial not allowed) (NOT-HG-21-043)
Notice to Extend Expiration Date for PAR-18-896: NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional) (NOT-LM-21-009)
Notice of Change to Key Dates for PAR-19-171 "Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)" (NOT-NS-22-011)
Notice of Change: Extension of PA-18-937 "Research on Chronic Overlapping Pain Conditions (R01 Clinical Trial Optional)" (NOT-NS-22-014)
Notice of Change: Extension of PA-18-939 "Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed)"(NOT-NS-22-015)
Notice of Special Interest: National Center for Complementary and Integrative Health (NCCIH) T32 Complementary and Integrative Health Practitioner Supplement Program for Pre- and Postdoctoral Candidates (NOT-AT-21-014)
Notice of Special Interest (NOSI): Advancing the development of tumor site-activated small molecules (NOT-CA-21-101)
Notice of Special Interest (NOSI): Program Priority Areas for MOSAIC UE5 - November 2021 Application Due Date (NOT-GM-21-051)
Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue) (NOT-HL-21-024)
Notice of Special Interest (NOSI): Administrative Supplements for NIMH Grants to Expand Perinatal Mental Health Interventions and Services Research (NOT-MH-21-215)
Notice of Special Interest (NOSI): Social, Behavioral, and Economic Impact of COVID-19 in Underserved and Vulnerable Populations (NOT-MH-21-330)
Please Note: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed) (PAR-21-271)- Deadline October 27, 2021
Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Required) (PAR-21-272) – Deadline October 27, 2021
Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Basic Experimental Studies with Humans Required (BESH)) (PAR-21-273) - Deadline October 27, 2021
Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Institutionally-Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed) (PAR-21-277) Deadline November 18, 2021 and November 15, 2022
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) (PAR-21-306) Deadline February 8, 2022 and June 7, 2022
Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional) (PAR-21-313) Deadline October 16, 2021 and February 16, 2022
Blueprint MedTech: Incubator Hubs (U54 Clinical Trial Not Allowed) (PAR-21-314) - Deadline October 20, 2021
Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional) (PAR-21-315) - Deadline October 20, 2021 and February 18, 2022
Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)
(PAR-21-316) – Deadline October 5, 2021 and February 5, 2022
Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed) (PAR-22-026) Deadline November 08, 2021
Limited Competition for the Continuation of Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed) (RFA-DK-21-503) - Deadline November 30, 2021
Innovative Multi-Level Approaches and Strategies to Prevent, Test and Treat HIV in Primary Care Settings in Health Disparity Populations in Geographic Hot Spots in the United States (R01 - Clinical Trial Required) (RFA-MD-22-001) – Deadline January 14, 2022
Deciphering Immune-CNS interactions in people living with HIV on Anti-Retroviral therapy (R01 Clinical Trial Optional) (RFA-MH-21-250) - Deadline December 07, 2021
Deciphering Immune-CNS interactions in HIV utilizing in-vitro and in-vivo model systems (R21 Clinical Trial Not Allowed) (RFA-MH-21-251) – Deadline December 07, 2021
Limited Competition: Genome Sequencing Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed) (RFA-RM-21-013) – Deadline October 29, 2021
OTHER FEDERAL DEADLINES
Department of Defense (DOD) – Melanoma Research Program (MRP) – Discovery Award – Required Letter of Intent due October 20, 2021
DOD – MRP – Mid-Career Accelerator Award – Required Letter of Intent due September 9, 2021
DOD – MRP – Team Science Award – Required Letter of Intent due September 9, 2021
DOD – MRP – Translational Research Award – Required Letter of Intent due September 9, 2021
Leukemia and Lymphoma Society – Equity in Access Research Program – Letter of Intent Deadline September 17, 2021